R&D channel feed

Bridge­Bio's make-or-break read­out is slat­ed for Mon­day, as CEO posts a cryp­tic mes­sage about Odysseus

Last year

Cari­bou’s off-the-shelf CAR-T ther­a­py shows hints of dura­bil­i­ty in ear­ly cut of da­ta 

Last year
Cell/Gene Tx

Roivant dis­cussing sale of its Pfiz­er-part­nered UC drug to Roche for $7B, ac­cord­ing to re­port

Last year
Deals

The­seus goes back to pre­clin­i­cal mode af­ter ax­ing lead tar­get­ed ther­a­py over tol­er­a­bil­i­ty con­cerns, shares plum­met

Last year

Pfiz­er clin­i­cal tri­al reg­istry aims to re­cruit one mil­lion peo­ple for re­search

Last year
Pharma
Marketing

First Wave’s mid-stage tri­al for yeast-de­rived cys­tic fi­bro­sis drug ‘like­ly’ failed, com­pa­ny says

Last year

From hours to min­utes? Genen­tech says Ocre­vus sub­cu­ta­neous for­mu­la­tion works just as well as IV

Last year

With biggest weight loss da­ta in hand, Eli Lil­ly races to start trio of PhI­II tri­als for its ‘triple-G’ can­di­date next month

Last year
Pharma

How many pa­tients could ben­e­fit from cus­tom ge­net­ic ther­a­pies? Tim­o­thy Yu nar­rows in on an an­swer

Last year
Cell/Gene Tx

In­cyte says JAK cream clears PhI­II eczema tri­al in chil­dren, but an­a­lysts are still watch­ing safe­ty

Last year
Pharma

ADC Ther­a­peu­tics paus­es Zyn­lon­ta tri­al en­roll­ment af­ter sev­en pa­tient deaths, five se­ri­ous safe­ty events

Last year

For­get TIG­IT: No­var­tis’ $1B bet on BeiGene’s ociper­limab ends af­ter com­peti­tors’ set­backs

Last year
Deals

Virid­i­an tar­gets Hori­zon's Te­pez­za with chron­ic thy­roid eye dis­ease da­ta, set­ting up the biotech for its sec­ond PhI­II

Last year

Mer­ck and Mod­er­na to start piv­otal can­cer vac­cine tri­al

Last year

FDA shifts how it pri­or­i­tizes which phar­ma sites to in­spect

Last year
Manufacturing

Aslan touts da­ta for com­peti­tor to Dupix­ent as it seeks new part­ners

Last year

Pen­ny stock biotech His­to­gen stops de­vel­op­ment pro­grams and con­sid­ers strate­gic al­ter­na­tives

Last year

Aus­tralia re­clas­si­fies psy­che­delics to fa­cil­i­tate med­ical use, as ad­vo­cates push for sim­i­lar move in US

Last year
Pharma

Mod­er­na pens deal with Chi­na to make mR­NA med­i­cines that 'will not be ex­port­ed'

Last year

'The more over­hype, the hard­er you fal­l': Schrödinger CEO warns on AI craze

Last year

De­fense De­part­ment en­lists Evotec to make new an­ti­body treat­ments for Mpox and oth­er pox­es

Last year
Deals

J&J will ad­vance pso­ri­a­sis drug li­censed from Pro­tag­o­nist af­ter fuller Phase IIb read­out

Last year
Pharma

As­traZeneca, Dai­ichi Sankyo claim PhI­II lung can­cer win for their next big ADC — but shares fall

Last year

FDA in­spec­tion at In­dia phar­ma at cen­ter of the cis­platin short­age cites mul­ti­ple qual­i­ty is­sues

Last year
Manufacturing
First page Previous page 76777879808182 Next page Last page
A service from the Financial Times